<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>keep exceeding</title>
  
  
  <link href="/atom.xml" rel="self"/>
  
  <link href="http://yoursite.com/"/>
  <updated>2020-03-06T08:36:39.493Z</updated>
  <id>http://yoursite.com/</id>
  
  <author>
    <name>FancyXie</name>
    
  </author>
  
  <generator uri="http://hexo.io/">Hexo</generator>
  
  <entry>
    <title></title>
    <link href="http://yoursite.com/2020/02/29/%E5%8D%95%E7%BB%86%E8%83%9E%E6%B5%8B%E5%BA%8F/Immunity--HPV+%E5%92%8CHPV-%E5%A4%B4%E9%A2%88%E7%99%8C%E6%82%A3%E8%80%85%E5%85%8D%E7%96%AB%E5%9B%BE%E8%B0%B1/"/>
    <id>http://yoursite.com/2020/02/29/单细胞测序/Immunity--HPV+和HPV-头颈癌患者免疫图谱/</id>
    <published>2020-02-29T08:22:25.724Z</published>
    <updated>2020-03-06T08:36:39.493Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Immunity-HPV-和HPV-头颈癌患者免疫图谱"><a href="#Immunity-HPV-和HPV-头颈癌患者免疫图谱" class="headerlink" title="Immunity | HPV+和HPV-头颈癌患者免疫图谱"></a>Immunity | HPV+和HPV-头颈癌患者免疫图谱</h1><p>Title: Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer </p><p>Immunity, 2020.01    <a href="https://doi.org/10.1016/j.immuni.2019.11.014" target="_blank" rel="noopener">https://doi.org/10.1016/j.immuni.2019.11.014</a>         </p><p>&nbsp;      </p><h2 id="Abstract"><a href="#Abstract" class="headerlink" title="Abstract"></a>Abstract</h2><p><strong>测序平台</strong>：10X</p><p><strong>样本</strong>: </p><ul><li><p>​    实验组：来自18个HPV– HNSCC 病人 和8个HPV+ HNSCC 病人的肿瘤组织及外周血的免疫细胞 （HNSCC：头颈癌）</p></li><li><p>​    对照组：来自5个睡眠呼吸暂停综合征患者的扁桃体组织和6份来自健康人的PBMC的免疫细胞</p></li></ul><p><strong>细胞量</strong>：经过质控，剩余131,224 个免疫细胞</p><p><strong>重点发现</strong>：</p><ul><li><p>HPV-HNSCC和HPV+HNSCC肿瘤微环境中免疫细胞转录组存在明显差异。主要差异体现在CD4辅助Tcell和Bcell。两种肿瘤中，CD8+Tcell以及Treg cell转录组相似</p></li><li><p>利用多光谱成像揭示HPV+病人中存在与疾病进展相关的免疫结构（TLSs）</p></li><li><p>TCGA数据显示, 滤泡辅助Tcell与头颈癌预后相关        </p><p>&nbsp;      </p></li></ul><h3 id="Introduction"><a href="#Introduction" class="headerlink" title="Introduction"></a>Introduction</h3><ul><li>头颈癌诱因：<ul><li>暴露于酒精或烟草等致癌物，引发基因改变</li><li>HPV感染</li></ul></li><li>HPV+HNSCC  预后更好</li><li>HPV+ HNSCC  肿瘤微环境中Bcell比例更高，HPV– HNSCC 中功能异常的CD8 Tcell比例更高</li><li>PD1或PDL1阻断疗法只对大约20%-30%的HNSCC病人有效        </li></ul><p>&nbsp;      </p><h3 id="Methods"><a href="#Methods" class="headerlink" title="Methods"></a>Methods</h3><ul><li><p><strong>单细胞建库：</strong>Chromium Single Cell 30 Reagent (V2 Chemistry) , 10X</p></li><li><p><strong>质控：</strong></p><ul><li>保留基因数在200-20,000之间的细胞</li><li>保留在超过1%细胞中表达，且表达量大于3 counts的基因</li><li>质控后，剩余131,224 个细胞，每个细胞平均表达1,262个基因</li></ul></li><li><p>使用TPM用于下游分析</p></li><li><p>Library size <strong>normalization</strong> ：log((每个细胞中某基因表达量*该细胞中基因总表达量)/10000 + 1)</p></li><li><p><strong>数据分析</strong>：</p><ul><li>数据的scale使用了Seurat软件</li><li>使用了两种降维方法： FItSNE  &amp; Diffusion Map（用于伪时序分析）</li><li>聚类方法：DRAGON （DeteRministic Annealing Gaussian mixture mOdel clusteriNg algorithm ）</li></ul></li><li><p><strong>类的注释</strong>：利用常规使用的marker</p></li><li><p><strong>寻找差异基因：</strong></p><ul><li>方法：Wilcoxon rank sum test </li><li>标准：在大于10%的细胞中表达，且差异倍数（logFC）大于0.5</li></ul></li><li><p><strong>下游分析：</strong></p><ul><li><p>利用R包SingleSeqGset 进行基因富集分析</p></li><li><p>利用Diffusion Map进行伪时序分析</p></li><li><p>计算亚群及样本间相关性</p></li><li><p>利用CellTalker，探索细胞亚群间cross-talk</p></li><li><p>TCGA数据分析        </p><p>&nbsp;        </p></li></ul></li></ul><h3 id="Results"><a href="#Results" class="headerlink" title="Results"></a>Results</h3><h4 id="Fig1"><a href="#Fig1" class="headerlink" title="Fig1:"></a>Fig1:</h4><ul><li>A: 流程</li><li>B：相关性分析: PBMC，TIL和扁桃体淋巴细胞以及HPV+和HPV- TIL在转录组上存在明显差异</li><li>C、D、E：聚类及注释</li><li>F： HPV-和HPV+ TIL相比比，Bcell，髓系细胞，CD4+ Tcon转录组差异较大，Treg和CD8细胞则比较相似</li></ul><p><img src="https://i.loli.net/2020/03/01/s79hAHJDnwilQoR.png" alt="snipaste20200301_222902.png"></p><p>​                    </p><h4 id="Fig2-CD8-Tcell"><a href="#Fig2-CD8-Tcell" class="headerlink" title="Fig2: CD8 Tcell"></a>Fig2: CD8 Tcell</h4><ul><li><p>B : cluster 1-4, 8主要来源于TIL；cluster 5-7由PBMC、扁桃体和TIL的混合组成</p></li><li><p>C: 每个cluster的marker   D：各亚群marker富集分析（biological functions）</p><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">cluster 1 was associated with cycling cells (e.g., MKI67); cluster 2 was associated with interferon (IFN) response genes (e.g., ISG15); clusters 3 and 4 expressed checkpoint markers associated with exhaustion (e.g., PDCD1 [gene for PD-1] andCTLA4andHAVCR2[gene for TIM3]); cluster 5 was generally quiescent and expressed low levels of effector molecules (e.g., GZMH and KLRD1); cluster 6 expressed markers associated with naive or memory cells (e.g., CCR7 andCD27); cluster 7 expressed genes associated with early activation (e.g., JUNB and FOSB); and cluster 8 expressed genes associated with effector function (e.g., KLRG1 and GZMH)</span><br></pre></td></tr></table></figure></li><li><p>E： 时序分析（diffusion map）显示PBMC和TIL间存在转化关系，Fig2F显示HPV+，HPV- CD8 Tcell转录组重叠</p><ul><li>DC1： 主要与终末分化表型相关（沿着DC1，LAG3, CTLA4, PDCD1 (gene for PD1) and HAVCR2 (gene for TIM3)表达量逐渐升高），除此之外还与细胞粘附和Bcell招募相关（ENTPD1和CXCL13）</li><li>DC2：主要与记忆表型相关（CD27, CCR7, EOMES）          </li></ul><p>​      </p></li></ul><p><img src="https://i.loli.net/2020/03/02/YCUXxmiGksR2H5M.png" alt="snipaste20200302_231255.png"></p><p>​                      </p><h4 id="Fig3-CD4-Tcell"><a href="#Fig3-CD4-Tcell" class="headerlink" title="Fig3: CD4+ Tcell"></a>Fig3: CD4+ Tcell</h4><p>分析思路类似于CD8</p><p>主要结论：</p><p><strong>CD4</strong>（Fig3A-Fig3E）</p><ul><li>扁桃体和TIL CD4 Tcell富集了TFH和TH1相关基因</li><li>HPV+ TIL富集更多的TFH基因</li><li>HPV+ TIL和HPV- TIL位于不同的分化界面上。CD4分化轨迹经历共同的起始阶段后，分别向cluster1和cluster7两个不同的终末分化状态转化。cluster1 主要来源于HPV+TIL，富集TFH相关基因。cluster7主要来源HPV- TIL，主要富集激活，IFN response，记忆相关基因</li></ul><p><strong>Treg</strong>（Fig3F-Fig3J）</p><ul><li>HPV+ Treg和HPV- Treg在时序上存在细微差异。分化早期，来自HPV-的Treg更多</li><li>分化早期的Treg富集IFN-response 基因（IFITM1, IFIT1, IFIT3, and ISG20）, 晚期主要富集TNF超家族基因（GITR， OX40，41BB），映证了TNF超家族基在维持Treg功能方面的作用        </li></ul><p>​         </p><p><img src="https://i.loli.net/2020/03/02/INohiMVAtu26Lb4.png" alt="snipaste20200302_231255.png"></p><p>​             </p><h4 id="Fig4：HPV-肿瘤微环境中发现生发中心（GC）B-cell"><a href="#Fig4：HPV-肿瘤微环境中发现生发中心（GC）B-cell" class="headerlink" title="Fig4：HPV+ 肿瘤微环境中发现生发中心（GC）B cell"></a>Fig4：HPV+ 肿瘤微环境中发现生发中心（GC）B cell</h4><ul><li>HPV+ 肿瘤微环境富含GC Bcell， 包括位于暗区的高增殖B细胞，和位于亮区的非增殖B细胞</li><li>HPV- 中的Bcell主要浆细胞和记忆Bcell，原因可能是因为缺乏TFH细胞的辅助      </li></ul><p>​         </p><p><img src="https://i.loli.net/2020/03/06/R8imdWCqcajJh9x.png" alt="snipaste20200306_143403.png"></p><p>​                     </p><h4 id="Fig5-Myeloid"><a href="#Fig5-Myeloid" class="headerlink" title="Fig5: Myeloid"></a>Fig5: Myeloid</h4><ul><li><p>PMBC中的髓系向肿瘤中髓系细胞转化</p></li><li><p>巨噬细胞不能简单分成M1和M2，它们之间存在连续变化的过渡关系（基本每种肿瘤的免疫细胞单细胞测序文章都提到了在这一点，没什么新意）       </p></li></ul><p><img src="https://i.loli.net/2020/03/06/b2f7eFx3gqm6acR.png" alt="snipaste20200306_155518.png">      </p><p>​          </p><h3 id="Fig6-免疫细胞间的cross-talk"><a href="#Fig6-免疫细胞间的cross-talk" class="headerlink" title="Fig6: 免疫细胞间的cross-talk"></a>Fig6: 免疫细胞间的cross-talk</h3><p>R包：celltalker</p><p>肿瘤组织中免疫细胞之间的cross-talk比癌旁和PBMC多</p><p>HPV+和HPV-肿瘤微环境中都存在独特的相互关系</p><p><img src="https://i.loli.net/2020/03/06/qrNYPehyVCE3dg7.png" alt="snipaste20200306_155518.png">      </p><p>​       </p><h4 id="Fig7：免疫荧光揭示独特的空间结构"><a href="#Fig7：免疫荧光揭示独特的空间结构" class="headerlink" title="Fig7：免疫荧光揭示独特的空间结构"></a>Fig7：免疫荧光揭示独特的空间结构</h4><ul><li>A：基于免疫细胞的组成不同，对不同slide进行了分层聚类</li><li>B-F：根据空间结构上的邻近程度，推测细胞细胞之间相互作用的几率。在B细胞频率最高的簇中，B细胞与其他B细胞相互作用的几率最高，其次是与CD4+Tconv细胞相互作用。并且，在5类cluster中，发现了反映三级淋巴结结构（TLSs）的免疫细胞组织模式</li><li>G-H: 根据空间结构上的推测出的相互作用关系，比较HPV+和HPV-肿瘤中Bcell与CD4+ Tconv间相互关系的差异。发现只有在HPV+肿瘤中存在GC Bcell与TFH的相互关系</li><li>I：利用TCGA数据库发现，在HPV+头颈癌病人中，TFH 基因集表达量高预示着更好的预后</li></ul><p><img src="https://i.loli.net/2020/03/06/16HfsSbwMKBcdTW.png" alt="snipaste20200306_155518.png"></p><h3 id="总结一下"><a href="#总结一下" class="headerlink" title="总结一下"></a>总结一下</h3><p>本文主要揭示HPV+和HPV-头颈癌病人免疫微环境的差异。其中最重要的差异在于HPV+病人中富集TFH，并存在TLSs。且TCGA分析显示TFH与预后相关。</p><p>总体来讲，本文的亮点在于实验设计上。取样取的很全面。既包括肿瘤组织，PBMC，又包括扁桃体。然后各种组织比来比去，总会找出很多差异的。至于文中用到的各种生信分析手段基本都是常规使用的分析套路。</p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;h1 id=&quot;Immunity-HPV-和HPV-头颈癌患者免疫图谱&quot;&gt;&lt;a href=&quot;#Immunity-HPV-和HPV-头颈癌患者免疫图谱&quot; class=&quot;headerlink&quot; title=&quot;Immunity | HPV+和HPV-头颈癌患者免疫图谱&quot;&gt;&lt;/a&gt;Imm
      
    
    </summary>
    
    
  </entry>
  
  <entry>
    <title></title>
    <link href="http://yoursite.com/2019/12/14/Review_Cancer-associated%20fibroblasts%20in%20gastrointestinal%20cancer/"/>
    <id>http://yoursite.com/2019/12/14/Review_Cancer-associated fibroblasts in gastrointestinal cancer/</id>
    <published>2019-12-14T15:09:01.159Z</published>
    <updated>2019-12-14T15:09:01.160Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Review-Cancer-associated-fibroblasts-in-gastrointestinal-cancer"><a href="#Review-Cancer-associated-fibroblasts-in-gastrointestinal-cancer" class="headerlink" title="Review | Cancer-associated fibroblasts in gastrointestinal cancer"></a>Review | Cancer-associated fibroblasts in gastrointestinal cancer</h1><p>Nature reviews | GastroenteroloGy &amp; HepatoloGy</p><p>2019</p><h2 id="Heterogeneity-of-CAFs"><a href="#Heterogeneity-of-CAFs" class="headerlink" title="Heterogeneity of CAFs"></a>Heterogeneity of CAFs</h2><h3 id="Marker-heterogeneity"><a href="#Marker-heterogeneity" class="headerlink" title="Marker heterogeneity"></a>Marker heterogeneity</h3><ul><li><p>Representative CAF markers include but are not limited to : αSMA ,FAP, FSP1(S100A4), PDGFRα, PDGFRβ</p></li><li><p>αSMA fails to distinguish all CAFs in the TME </p></li><li><p>none of these CAF markers are specific to CAFs, as they are also expressed in other cell types and healthy tissues </p></li><li><p>FAP+CD45+ cells also correspond to a subset of tumor-associated macrophages </p></li><li><p>FSP1 also mark epithelial cells undergoing EMT and inflammatory macrophages </p><p>​      </p></li></ul><p>tumor-promoting CAFs (pCAFs), tumor-retarding CAFs (rCAFs) and neutral CAFs (nCAFs) </p><p>rCAFs, pCAFs, secretory CAFs, inflammatory CAFs and myofibroblastic CAFs </p><h4 id="single-cell-RNA-sequencing-analyses-from-human-CRC-samples"><a href="#single-cell-RNA-sequencing-analyses-from-human-CRC-samples" class="headerlink" title="single-cell RNA sequencing analyses from human CRC samples"></a>single-cell RNA sequencing analyses from human CRC samples</h4><p>two major subtypes :</p><ul><li><p>CAF-As : MMP2, DCN, FAP, COL1A2</p></li><li><p>CAF-Bs:  characterized by high expression of myofibroblastic markers such as αSMA, transgelin(TAGLN) and PDGFα </p></li></ul><h3 id="Functional-heterogeneity"><a href="#Functional-heterogeneity" class="headerlink" title="Functional heterogeneity"></a>Functional heterogeneity</h3><ul><li><p>CAFs co-injected into mice with human breast cancer cells promote tumor growth and angiogenesis more than normal fibroblasts through secretion of CXC-chemokine ligand 12 (CXCL12; also known as SDF1) </p></li><li><p>IκB kinase-β (IKKβ)-mediated nuclear factor-κB (NF-κB) activation in CAFs is responsible for inducing tumor-promoting inflammation in a mouse model of skin carcinogenesis </p></li><li><p>the genetic deletion of IKKβ in collagen type VI (COLVI)+ fibroblasts resulted in reduced tumor growth and immune cell infiltration in a mouse model of colitis-associated cancer (CAC) via decreased IL-6 production by IKKβ-deficient CAFs </p></li><li><p>genetic deletion of IKKβ in a larger population of COL1A2+ fibroblasts in a similar CAC model unexpectedly accelerated tumor growth through enhanced hepatocyte growth factor (HGF) secretion</p></li><li>FAP knockout impaired development of PDAC in KPC mice and subcutaneously injected colon cancer in mice  FAP has a tumour-promoting function. In humans, elevated expression of FAP in the stroma of CRC and PDAC has been shown to correlate with poor patient prognosis <strong>FAP could be a candidate marker for pCAFs</strong> </li></ul><p>​            </p><h3 id="Intratumoural-heterogeneity"><a href="#Intratumoural-heterogeneity" class="headerlink" title="Intratumoural heterogeneity"></a>Intratumoural heterogeneity</h3><ul><li>PDAC :<ul><li><font color="#DC143C"><strong>αSMAhiIL-6low myofibroblastic CAFs</strong></font>:  marked by expression of myofibroblast genes and<br>TGFβ-responsive genes such as <strong>ACTA2, CTGF (also known as CCN2) and COL1A1 &amp; located adjacent to cancer cells</strong> </li><li><font color="#DC143C"><strong>αSMAlowIL-6hi inflammatory CAFs</strong>  </font>: secrete inflammatory cytokines and chemokines such as <strong>IL-6, IL-11, CXCL1 and leukaemia inhibitory factor (LIF) &amp; located distantly from cancer cells</strong> </li><li>TGFβ signalling and IL-1–JAK–STAT signalling are responsible for inducing differentiation of pancreatic stellate cells, which serve as precursors for CAFs as they transition into myofibroblastic CAFs and inflammatory CAFs, respectively  <strong>TGFβ信号和STAT信号介导CAF分化</strong></li></ul></li></ul><h3 id="Origin-of-CAFs"><a href="#Origin-of-CAFs" class="headerlink" title="Origin of CAFs"></a>Origin of CAFs</h3><p><img src="C:\Users\feng\AppData\Roaming\Typora\typora-user-images\1576313414345.png" alt="1576313414345"></p><p>&nbsp;</p><h2 id="Function-of-CAFs"><a href="#Function-of-CAFs" class="headerlink" title="Function of CAFs"></a>Function of CAFs</h2><h3 id="Stromal-and-epithelial-interactions"><a href="#Stromal-and-epithelial-interactions" class="headerlink" title="Stromal and epithelial interactions"></a>Stromal and epithelial interactions</h3><p>CAFs directly confer growth advantages to cancer cells </p><p>&nbsp;</p><h4 id="Paracrine-signalling"><a href="#Paracrine-signalling" class="headerlink" title="Paracrine signalling"></a>Paracrine signalling</h4>]]></content>
    
    <summary type="html">
    
      
      
        &lt;h1 id=&quot;Review-Cancer-associated-fibroblasts-in-gastrointestinal-cancer&quot;&gt;&lt;a href=&quot;#Review-Cancer-associated-fibroblasts-in-gastrointestinal-
      
    
    </summary>
    
    
  </entry>
  
  <entry>
    <title>单细胞测序发现保守的肺癌髓系细胞群</title>
    <link href="http://yoursite.com/2019/05/26/%E5%8D%95%E7%BB%86%E8%83%9E%E6%B5%8B%E5%BA%8F%E5%8F%91%E7%8E%B0%E4%BF%9D%E5%AE%88%E7%9A%84%E8%82%BA%E7%99%8C%E9%AB%93%E7%B3%BB%E7%BB%86%E8%83%9E%E7%BE%A4/"/>
    <id>http://yoursite.com/2019/05/26/单细胞测序发现保守的肺癌髓系细胞群/</id>
    <published>2019-05-26T03:25:14.000Z</published>
    <updated>2019-06-03T13:58:58.601Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Title"><a href="#Title" class="headerlink" title="Title"></a>Title</h1><p>文章标题</p><h2 id="Summary"><a href="#Summary" class="headerlink" title="Summary"></a>Summary</h2><p>写完笔记之后最后填，概述文章的内容，以后查阅笔记的时候先看这一段。</p><h2 id="Research-Objective"><a href="#Research-Objective" class="headerlink" title="Research Objective"></a>Research Objective</h2><p>作者的研究目标。</p><h2 id="Problem-Statement"><a href="#Problem-Statement" class="headerlink" title="Problem Statement"></a>Problem Statement</h2><p>问题陈述，要解决什么问题？</p><h2 id="Method-s"><a href="#Method-s" class="headerlink" title="Method(s)"></a>Method(s)</h2><p>解决问题的方法/算法是什么？</p><h2 id="Evaluation"><a href="#Evaluation" class="headerlink" title="Evaluation"></a>Evaluation</h2><p>作者如何评估自己的方法，有没有问题或者可以借鉴的地方。</p><h2 id="Conclusion"><a href="#Conclusion" class="headerlink" title="Conclusion"></a>Conclusion</h2><p>作者给了哪些strong conclusion, 又给了哪些weak conclusion?</p><h2 id="Notes"><a href="#Notes" class="headerlink" title="Notes"></a>Notes</h2>]]></content>
    
    <summary type="html">
    
      
      
        &lt;h1 id=&quot;Title&quot;&gt;&lt;a href=&quot;#Title&quot; class=&quot;headerlink&quot; title=&quot;Title&quot;&gt;&lt;/a&gt;Title&lt;/h1&gt;&lt;p&gt;文章标题&lt;/p&gt;
&lt;h2 id=&quot;Summary&quot;&gt;&lt;a href=&quot;#Summary&quot; class=&quot;header
      
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>cDC2的亚群可以prime CD4</title>
    <link href="http://yoursite.com/2019/05/24/cDC2%E7%9A%84%E4%BA%9A%E7%BE%A4%E5%8F%AF%E4%BB%A5prime%20CD4/"/>
    <id>http://yoursite.com/2019/05/24/cDC2的亚群可以prime CD4/</id>
    <published>2019-05-24T01:19:46.000Z</published>
    <updated>2019-05-24T11:58:12.777Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://doi.org/10.1016/j.cell.2019.02.005" target="_blank" rel="noopener">Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity</a></p><h1 id="Introduction"><a href="#Introduction" class="headerlink" title="Introduction"></a>Introduction</h1><p>目前，免疫抑制剂治疗疗效不佳的原因之一是因为存在dysfunction或exhausted的T。而且这种耗竭的状态无法被免疫检查点抑制剂逆转</p><p>antitumor中，CD4的作用：</p><ul><li>Effector CD4+ Tconv can augment immunity by licensing dendritic cells (DC) and stimulating pro-inflammatory myeloid cell programs</li><li>Effective anti- CTLA-4 therapy generates <strong>ICOS+PD-1lo </strong>CD4+ T helper 1-like (Th1-like) effector CD4+ Tconv critical for an antitumor response</li><li>Presence of PD-1hi CD4+ Tconv cells, correlated with high tumor burden and likely T cell exhaustion, is a negative prognostic indicator for ICB</li></ul><p>在浸润肿瘤前，T细胞现在肿瘤引流淋巴结（tumor-draining lymph node (tdLN)）中由cDC激活</p><p>cDC：</p><ul><li>cDC can be divided into cDC1 and cDC2 populations that are either LN resident or migrate to the LN from peripheral tissues</li><li>cDC1 are critical for directing CD8+ T cell immunity to various pathogens</li><li>cDC2, a heterogeneous population, preferentially initiate CD4+ Tconv responses in several conditions</li></ul><h1 id="Results"><a href="#Results" class="headerlink" title="Results"></a>Results</h1><h2 id="Myeloid-Heterogeneity-at-Single-Cell-Resolution"><a href="#Myeloid-Heterogeneity-at-Single-Cell-Resolution" class="headerlink" title="Myeloid Heterogeneity at Single-Cell Resolution"></a>Myeloid Heterogeneity at Single-Cell Resolution</h2>]]></content>
    
    <summary type="html">
    
      
      
        &lt;p&gt;&lt;a href=&quot;https://doi.org/10.1016/j.cell.2019.02.005&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Unleashing Type-2 Dendritic Cells to Drive Protective
      
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>CAF associated papers</title>
    <link href="http://yoursite.com/2019/05/20/CAF-associated-papers/"/>
    <id>http://yoursite.com/2019/05/20/CAF-associated-papers/</id>
    <published>2019-05-20T07:21:46.000Z</published>
    <updated>2019-05-20T14:16:36.769Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Fibroblasts-in-cancer"><a href="#Fibroblasts-in-cancer" class="headerlink" title="Fibroblasts in cancer"></a>Fibroblasts in cancer</h1><p>The important functions of fibroblasts include the deposition of extracellular matrix (ECM), regulation of epithelial differentiation, regulation of inflammation, and involvement in wound healing</p><a id="more"></a><p><a href="doi:10.1038/nrc1877" target="_blank" rel="noopener">Fibroblasts in cancer</a></p><h2 id="The-tumour-stroma"><a href="#The-tumour-stroma" class="headerlink" title="The tumour stroma"></a>The tumour stroma</h2><p>Normal stroma in most organs contains a minimal number of fibroblasts in association with a physiological ECM. Reactive stroma is associated with an increased number of fibroblasts, enhanced capillary density, and type-I-collagen and fibrin deposition.</p><p>&nbsp;</p><p><img src="https://i.loli.net/2019/04/09/5cac5243ebdef.jpg" alt></p><p>In chickens that are cancer-prone because they have been infected with Rous sarcoma virus, wounding leads to invasive carcinomas within tissues that would other- wise remain tumour-free. This demonstrates that reactive stroma provides oncogenic signals to facilitate tumorigenesis.</p><p>&nbsp;</p><p>Vascular endothelial growth factor (VEGF, also known as vascular permeability factor (VPF)) has a central role in the emergence of the reactive stroma</p><p><strong>VEGF induces microvascular permeability</strong>, which leads to the extravasation of plasma proteins such as fibrin, which in turn attract an influx of fibroblasts, inflammatory cells and endothelial cells. These cells produce ECM(extracellular matrix) that is rich in fibronectin and type I collagen, both of which are conducive to initiating tumour angiogenesis</p><p>carcinoma in situ (CIS)</p><p>&nbsp;</p><p><strong>Tenascin C</strong> is absent in the normal adult mammary gland, but  expression is regularly seen in mammary tumours. Increased tenascin-C expression correlates with poor prognosis for both <strong>breast cancer and bladder cancer</strong>.</p><p>&nbsp;</p><p>There are several well-established indicators of fibroblast phenotype, but none of them are both exclusive to fibroblasts and present in all fibroblasts (see table). Among all of the known markers, fibroblast-specific protein 1 (<strong>FSP1</strong>) seems to provide the best specificity for detecting fibroblasts in vivo. <strong>Desmin</strong> is a specific marker for fibroblasts in the skin, whereas it is strongly expressed in muscle cells in other sites</p><p>Fetal skin fibroblasts express high levels of collagen types I and V, whereas fetal lung fibroblasts do not. Also, fetal lung fibroblasts exclusively express the lung-specific forkhead family transcription factors <strong>FOXF1</strong> and <strong>FOXP1</strong></p><p>&nbsp;</p><p>Injection of <strong>L-3,4 dehydroproline</strong> (which inhibits the formation of collagen fibrils) increases tumour cell invasion in a mouse model of B16F10 melanoma subcutaneous tumours</p><p>&nbsp;</p><p><img src="https://i.loli.net/2019/04/09/5cacbb9c1f275.jpg" alt></p><p>&nbsp;</p><h2 id="Carcinoma-associated-fibroblasts"><a href="#Carcinoma-associated-fibroblasts" class="headerlink" title="Carcinoma-associated fibroblasts"></a>Carcinoma-associated fibroblasts</h2><p>In the absence of electron microscopy validation, CAFs are commonly identified by their expression of <font color="#F08080"><strong>α-smooth-muscle actin</strong></font></p><p>The signals that mediate the transition of a normal fibroblast into a CAF are not fully understood. In culture, phenotypic features of CAFs can be induced by transforming growth factor-β (TGFβ), which mediates fibroblast activation during wound healing and organ fibrosis.Therefore, similar pathways might also be responsible for the emergence of CAFs in tumours.</p><p>&nbsp;</p><p><img src="https://i.loli.net/2019/04/09/5cacbbf68b1dc.jpg" alt></p><p>&nbsp;</p><h2 id="Growth-factors-and-fibroblasts"><a href="#Growth-factors-and-fibroblasts" class="headerlink" title="Growth factors and fibroblasts"></a>Growth factors and fibroblasts</h2><p>Tumour stroma volume and composition are partly governed by the response of fibroblasts to the pro-fibrotic growth factors that are released by the cancer cells— for example, TGFβ, platelet-derived growth factor (PDGF) and fibroblast growth factor 2 (FGF2)</p><p>PDGF is another growth factor that is secreted by can- cer cells and correlates with cancer progression.As opposed to TGFβ, PDGF induces the proliferation of fibroblasts, but does not induce the acquisition of an activated phenotype that is associated with excessive ECM deposition</p><p>&nbsp;</p><h2 id="EMT-as-a-source-of-CAFs"><a href="#EMT-as-a-source-of-CAFs" class="headerlink" title="EMT as a source of CAFs"></a>EMT as a source of CAFs</h2><p>In epithelial-to-mesenchymal transition (EMT), epithelial cells lose cell–cell contacts and acquire mesenchymal properties. Cancer cells undergoing EMT develop invasive and migratory abilities</p><p>EMT involving normal epithelial cells that are adjacent to malignant cancer cells might also contribute to the emergence of CAFs</p><p>&nbsp;</p><h2 id="The-role-of-CAFs-in-the-initiation-of-cancer"><a href="#The-role-of-CAFs-in-the-initiation-of-cancer" class="headerlink" title="The role of CAFs in the initiation of cancer"></a>The role of CAFs in the initiation of cancer</h2><p>Overexpression of TGFβ and/or hepatocyte growth factor (<font color="#F08080"><strong>HGF</strong></font>) in mouse fibroblasts induces the initiation of breast cancer within the normal human epithelium.</p><p>&nbsp;</p><p><img src="https://i.loli.net/2019/04/12/5cb0933d9c560.jpg" alt></p><p>&nbsp;</p><h2 id="The-role-of-CAFs-in-the-progression-of-cancer"><a href="#The-role-of-CAFs-in-the-progression-of-cancer" class="headerlink" title="The role of CAFs in the progression of cancer"></a>The role of CAFs in the progression of cancer</h2><p>Ras-transformed human MCF-7 breast cancer cells (which form tumours and metastasize independent of oestrogen) were co-injected subcutaneously into nude mice in suspension with CAFs or normal fibroblasts The results showed that xenografts containing CAFs grew larger than xenografts infused with normal fibroblasts<br>Such enhanced growth was associated with increased cancer-cell proliferation (but not increased fibroblast pro- liferation) and more angiogenesis, indicating that CAFs might have a bi-modal effect during tumorigenesis</p><p>既能促进癌细胞的增殖，又能促进血管的生成</p><p>CAF-derived stromal- cell-derived factor 1 (<font color="#F08080"><strong>SDF1</strong></font>) mediates the recruitment of bone-marrow-derived endothelial cells and directly increases the proliferation of MCF-Ras cancer cells</p><p>Activated fibroblasts are a source of ECM-degrading proteases such as the MMPs. MMPs probably allow cancer cells to cross tissue boundaries and escape the primary tumour site.</p><font color="#F08080"><strong>MMP3</strong></font> (also known as stromelysin 1) is highly expressed in fibroblasts<br><br>MMP3 directly cleaves the extra- cellular domain of E-cadherin, prompting normal mammary epithelial cells to disaggregate and undergo EMT, promoting cancer-cell invasiveness. MMP1 also shows such a tumour-promoting effect. The protease-activated receptor <font color="#F08080"><strong>PAR1</strong></font>, which is a tethered-ligand receptor, is activated by proteolytic cleavage of the extracellular domain by MMP1, promoting cancer cell migration and invasion through PAR1-dependent Ca2+ signals<br><br>(MMP3和MMP1切割E-钙黏蛋白的胞外结构域，从而激活PAR1。PAR1通过Ca2+信号促进癌细胞的迁移)<br><br>&nbsp;<br><br>## The role of CAFs in metastasis<br><br>only the melanoma cells that metastasized were influenced by fibroblasts. This indicates that specific stimuli provided by fibroblasts create a niche that promotes the growth of subsets of cancer cells at distant sites. Tumour growth and metastasis in FSP1-deficient mice (FSP1-deficient fibroblasts show decreased motility) is significantly reduced.<br><br>&nbsp;&nbsp;<br><br>## Fibroblasts and TGFβ<br><br>TGFβ has a role in the recruitment of fibroblasts. However, TGFβ is also the most prominent of the factors within the tumour micro- environment that are known to induce EMT of cancer cells. Before the initiation of cancer, and during the early stages of carcinogenesis, TGFβ probably functions as a tumour suppressor. By contrast, during advanced stages of cancer, TGFβ signalling promotes cancer progression and metastasis.<br><br>In normal tissues, the anti-proliferative and proapoptotic response of epithelial cells to TGFβ might limit the growth of normal epithelium and the emergence of malignant carcinomas. With regard to fibroblasts,TGFβ facilitates fibroblast–epithelial-cell interactions, which further suppress cancer initiation. In advanced cancer, on the other hand, the anti-proliferative effect of TGFβ is progressively lost — instead, it facilitates EMT of cancer cells, potentially promoting invasiveness and metastasis. Signalling pathways that are implicated in TGFβ-mediated EMT involve  <font color="#F08080"><strong>Smad</strong></font> signalling, the <font color="#F08080"><strong>phosphatidylinositol-3-kinase–Akt</strong></font> pathway and signalling through <font color="#F08080"><strong>RHOA</strong></font> and <font color="#F08080"><strong>p38 MAPK</strong></font><p>(其中Smad可能是起决定作用的通路)</p><p>&nbsp;</p><p><img src="https://i.loli.net/2019/04/12/5cb0937f9bfc0.jpg" alt></p><p>&nbsp;</p><h2 id="Fibroblasts-in-the-host-defence-against-cancer"><a href="#Fibroblasts-in-the-host-defence-against-cancer" class="headerlink" title="Fibroblasts in the host defence against cancer?"></a>Fibroblasts in the host defence against cancer?</h2><p>Fibroblasts that overexpress TGFβ and HGF promote tumorigenic outgrowth of normal breast epithelium, but such outgrowth is inhibited by ‘normal’ stromal fibroblasts. One possible mechanism for such a function of fibroblasts in host defence is modulation of the immune response. Fibroblasts are a signficant source of immune-modulatory cytokines such as interferon-γ, interleukin-6 and tumour-necrosis factor-α which can influence the mobilization of cytotoxic T lymphocytes, natural killer cells and macrophages. In this regard, it has also been suggested that normal fibroblasts help to prevent apoptosis of T cells</p><p>(活化的fibroblast促进癌症，normal fibroblast抑制癌症)</p><p>&nbsp;</p><h2 id="Therapies-to-target-activated-fibroblasts"><a href="#Therapies-to-target-activated-fibroblasts" class="headerlink" title="Therapies to target activated fibroblasts"></a>Therapies to target activated fibroblasts</h2><p>Fibroblast-directed therapy can be envisioned as either ‘to ablate’ or ‘to normalize’ CAFs. The cell-surface serine protease known as fibroblast activation protein (<font color="#F08080"><strong>FAP</strong></font>) emerges as a promising candidate for specifically targetting CAFs. FAP is not expressed by mature somatic tissues except for activated fibroblasts during wound healing and within tumour stroma.</p><p>HGF inhibits the activation and progression of tissue fibrosis in several animal models of chronic disease, and HGF overexpression prevents fibrosis in the liver and kidneys. However, numerous studies have implied that HGF promotes the malignant transformation of epithelial cells and also promotes cancer progression</p><h1 id="Distinct-populations-of-inflammatory-fibroblasts-and-myofibroblasts-in-pancreatic-cancer"><a href="#Distinct-populations-of-inflammatory-fibroblasts-and-myofibroblasts-in-pancreatic-cancer" class="headerlink" title="Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer"></a>Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer</h1><p><a href="http://doi.org/10.1084/jem.20162024" target="_blank" rel="noopener">http://doi.org/10.1084/jem.20162024</a></p>]]></content>
    
    <summary type="html">
    
      &lt;h1 id=&quot;Fibroblasts-in-cancer&quot;&gt;&lt;a href=&quot;#Fibroblasts-in-cancer&quot; class=&quot;headerlink&quot; title=&quot;Fibroblasts in cancer&quot;&gt;&lt;/a&gt;Fibroblasts in cancer&lt;/h1&gt;&lt;p&gt;The important functions of fibroblasts include the deposition of extracellular matrix (ECM), regulation of epithelial differentiation, regulation of inflammation, and involvement in wound healing&lt;/p&gt;
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="cancer" scheme="http://yoursite.com/tags/cancer/"/>
    
  </entry>
  
  <entry>
    <title>PD-1治疗需要CXCR3</title>
    <link href="http://yoursite.com/2019/05/20/PD-1%E6%B2%BB%E7%96%97%E9%9C%80%E8%A6%81CXCR3/"/>
    <id>http://yoursite.com/2019/05/20/PD-1治疗需要CXCR3/</id>
    <published>2019-05-20T01:36:46.000Z</published>
    <updated>2019-05-20T01:49:03.815Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://www.cell.com/immunity/fulltext/S1074-7613(19" target="_blank" rel="noopener">Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy</a>30190-6?rss=yes)</p><a id="more"></a><h2 id="Abstract"><a href="#Abstract" class="headerlink" title="Abstract"></a>Abstract</h2><p>作者发现缺乏趋化因子受体CXCR3的荷瘤小鼠对抗PD-1治疗的反应很差。 在用抗PD-1处理的荷瘤小鼠中，CXCR3及其配体CXCL9对于productive CD8 + T细胞应答是关键的，但对于CD8 + T细胞向肿瘤的浸润不是必需的。瘤内CD103 +树突细胞产生的CXCL9促进了抗PD-1诱导的抗肿瘤反应，表明CXCR3促进肿瘤微环境中的DC-T细胞相互作用。小鼠肿瘤和黑素瘤患者血浆中的CXCR3配体是对抗PD-1的临床反应的指标，并且在非反应性小鼠肿瘤中诱导CXCL19表达可以促进抗PD-1的反应性。综上：CXCR3趋化因子系统是对PD-1阻断敏感性的生物标志物，并且增强该趋化因子系统的肿瘤内功能可以改善clinical outcome</p><p><img src="https://marlin-prod.literatumonline.com/cms/attachment/10b461fe-0506-43fb-9897-46bc720b5b1a/fx1_lrg.jpg" alt></p>]]></content>
    
    <summary type="html">
    
      &lt;p&gt;&lt;a href=&quot;https://www.cell.com/immunity/fulltext/S1074-7613(19&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy&lt;/a&gt;30190-6?rss=yes)&lt;/p&gt;
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>TGF-β--肿瘤免疫</title>
    <link href="http://yoursite.com/2019/05/17/TGF-%CE%B2--%E8%82%BF%E7%98%A4%E5%85%8D%E7%96%AB/"/>
    <id>http://yoursite.com/2019/05/17/TGF-β--肿瘤免疫/</id>
    <published>2019-05-17T08:12:22.000Z</published>
    <updated>2019-05-20T01:36:50.175Z</updated>
    
    <content type="html"><![CDATA[<h1 id="概况"><a href="#概况" class="headerlink" title="概况"></a>概况</h1><p>TGF-β在肿瘤早期可以抑制肿瘤生长，而在后期则转变成一个肿瘤促进因子。</p><p>晚期，大多数肿瘤细胞均可分泌TGF-β，一旦TGF-β水平升高便可以<strong>阻断未成熟的T细胞向Th1细胞分化，促进其向Treg亚群的转化，并抑制树突状细胞的抗原递呈功能</strong>，从而导致肿瘤细胞的免疫逃逸。随着肿瘤的发展，肿瘤细胞内TGF-β受体或其下游的<em>Smad</em>基因突变积累，其抑制作用减弱。并且<strong>TGF-β信号促进上皮细胞间质转型</strong>（Epithelial-Mesenchymal Transition, EMT），这个过程使具有极性的上皮细胞转化为具有活动能力的间质细胞，从而获得侵袭和迁移的能力，这个转化过程在肿瘤的发生、恶化及转移中非常重要。肿瘤转移是导致癌症病人死亡的一个非常重要的原因，实体瘤患者中高达90%的患者死于肿瘤转移。</p><h1 id="文献"><a href="#文献" class="headerlink" title="文献"></a>文献</h1><h2 id="TGFβ-drives-immune-evasion-in-genetically-reconstituted-colon-cancer-metastasis"><a href="#TGFβ-drives-immune-evasion-in-genetically-reconstituted-colon-cancer-metastasis" class="headerlink" title="TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis"></a>TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis</h2>]]></content>
    
    <summary type="html">
    
      
      
        &lt;h1 id=&quot;概况&quot;&gt;&lt;a href=&quot;#概况&quot; class=&quot;headerlink&quot; title=&quot;概况&quot;&gt;&lt;/a&gt;概况&lt;/h1&gt;&lt;p&gt;TGF-β在肿瘤早期可以抑制肿瘤生长，而在后期则转变成一个肿瘤促进因子。&lt;/p&gt;
&lt;p&gt;晚期，大多数肿瘤细胞均可分泌TGF-β，一旦TGF-
      
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>统计</title>
    <link href="http://yoursite.com/2019/05/15/%E7%BB%9F%E8%AE%A1/"/>
    <id>http://yoursite.com/2019/05/15/统计/</id>
    <published>2019-05-15T02:54:31.000Z</published>
    <updated>2019-05-15T02:59:22.220Z</updated>
    
    <content type="html"><![CDATA[<h1 id="生存曲线比较-Log-Rank检验"><a href="#生存曲线比较-Log-Rank检验" class="headerlink" title="生存曲线比较: Log Rank检验"></a>生存曲线比较: Log Rank检验</h1><blockquote><p>1、SPSS中的分析方法的名称为Log Rank和Breslow；SAS中相对应的为Log Rank和Wilcoxon。Breslow法即广义Wilcoxon法。Log Rank检验在实际工作中应用较多。</p></blockquote><p>2、Log Rank检验给结局事件的远期差别更大的权重，即对远期差异敏感；而Breslow检验给结局事件的近期差别更大的权重。因此，对于一开始粘在一起，随时时间的推移越拉越开的生存曲线，Log Rank检验较Breslow检验容易得到差异有显著性的结果；反之，对于一开始相差较大，随着时间的推移反而越来越近的生存曲线，Breslow法容易得到差异有显著性的结果。</p><p>3、用Log Rank检验比较时，要求各组生存曲线不能交叉，如果有交叉则提示可能存在混杂因素，此时应进行样本分层或多因素的方法校正混杂因素。</p><p><a href="https://zhuanlan.zhihu.com/p/24410512" target="_blank" rel="noopener">生存曲线比较：KM法及Log Rank检验（实例+SPSS）</a></p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;h1 id=&quot;生存曲线比较-Log-Rank检验&quot;&gt;&lt;a href=&quot;#生存曲线比较-Log-Rank检验&quot; class=&quot;headerlink&quot; title=&quot;生存曲线比较: Log Rank检验&quot;&gt;&lt;/a&gt;生存曲线比较: Log Rank检验&lt;/h1&gt;&lt;blockquote
      
    
    </summary>
    
      <category term="basic" scheme="http://yoursite.com/categories/basic/"/>
    
    
      <category term="statistics" scheme="http://yoursite.com/tags/statistics/"/>
    
  </entry>
  
  <entry>
    <title>pancreatic CAF associated papers</title>
    <link href="http://yoursite.com/2019/05/15/pancreatic-CAF-associated-papers/"/>
    <id>http://yoursite.com/2019/05/15/pancreatic-CAF-associated-papers/</id>
    <published>2019-05-15T02:44:13.000Z</published>
    <updated>2019-05-20T07:13:51.823Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864274/" target="_blank" rel="noopener">Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer</a></p><p>PNAS, 2013</p><a id="more"></a><p>在胰腺癌中，α-CTLA-4 and α-PD-L1治疗效果不佳。</p><p> ELISpots 显示， 来自肿瘤的CD8 T细胞中 IFN-γ–secreting CD8+ T cells 更多。而且The frequency of IFN-γ–secreting CD8+ T cells was the same when the stimulating tumor cells were from the T-cell donor or from another PDA-bearing mouse</p><p><strong>Conclusion</strong>：PDA荷瘤小鼠对于肿瘤抗原有自发适应性免疫。免疫抑制剂疗效不佳，有别的原因</p><p>FAP+ cells were present in PanIN and both cytokeratin-19+ (CK19+) and CK19− PDA lesions but rarely α-smooth muscle actin (αSMA), whereas FAP+ cells among PDA cells were CD34−and αSMA+ </p><p>All FAP+ cells were PDGF receptor-α+ and CD45−, confirming their mesenchymal origin</p><p>RNAseq 显示胰腺癌中FAP+细胞编码基因与细胞外基质蛋白相关</p><p>Depleting FAP+ cells slowed PDA growth, but not when CD4+ and CD8+ T cells were removed. Combining depletion of FAP+ cells with administration of α-CTLA-4 or α-PD-L1 further diminished tumor growth.</p><p><strong>Conclusion</strong>：FAP+ 细胞介导PDA对于免疫抑制剂的抵抗作用</p><p>DTx- and α-PD-L1–treated mice 中IFN-γ–secreting CD8+ T cells并没有增加。</p><p><strong>Conclusion</strong>：FAP的作用并不是通过诱导CD8细胞</p><p>癌旁缺乏CD3+ T细胞，原因是因为CXCL12。作者发现肿瘤中FAP+ 细胞是CXCL12的唯一来源。但是CXCL12定位在肿瘤细胞上，可能是metabolically stressed cancer cells过表达并分泌HMGB1捕获CXCL12并形成高亲和力的复合物。</p><p>使用CXCR4抑制剂 AMD3100， 证实了CXCL12的作用。Tumor growth was slowed by AMD3100 in a T cell-dependent manner。 CXCR4-mediated exclusion of T cells reflects T-cell apoptosis</p><p><img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864274/figure/fig04/" alt></p>]]></content>
    
    <summary type="html">
    
      &lt;p&gt;&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864274/&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;PNAS, 2013&lt;/p&gt;
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="cancer" scheme="http://yoursite.com/tags/cancer/"/>
    
  </entry>
  
  <entry>
    <title>R: Error in dyn.load(file, DLLpath = DLLpath, …)</title>
    <link href="http://yoursite.com/2019/05/12/R-Error-in-dyn-load-file-DLLpath-DLLpath-%E2%80%A6/"/>
    <id>http://yoursite.com/2019/05/12/R-Error-in-dyn-load-file-DLLpath-DLLpath-…/</id>
    <published>2019-05-12T14:05:26.000Z</published>
    <updated>2019-05-12T14:07:21.342Z</updated>
    
    <content type="html"><![CDATA[<figure class="highlight r"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br></pre></td><td class="code"><pre><span class="line">Re-installing the package was enough to getting it working again.</span><br><span class="line">$ sudo R</span><br><span class="line">&gt; install.packages(<span class="string">"rgdal"</span>)</span><br><span class="line">&gt; quit()</span><br><span class="line">$ exit</span><br></pre></td></tr></table></figure><p><a href="https://stackoverflow.com/questions/38943764/r-error-in-dyn-loadfile-dllpath-dllpath" target="_blank" rel="noopener">https://stackoverflow.com/questions/38943764/r-error-in-dyn-loadfile-dllpath-dllpath</a></p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;figure class=&quot;highlight r&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;li
      
    
    </summary>
    
      <category term="erro" scheme="http://yoursite.com/categories/erro/"/>
    
    
      <category term="R" scheme="http://yoursite.com/tags/R/"/>
    
  </entry>
  
  <entry>
    <title>R install.packages returns “failed to create lock directory</title>
    <link href="http://yoursite.com/2019/05/12/R-install-packages-returns-%E2%80%9Cfailed-to-create-lock-directory/"/>
    <id>http://yoursite.com/2019/05/12/R-install-packages-returns-“failed-to-create-lock-directory/</id>
    <published>2019-05-12T13:55:30.000Z</published>
    <updated>2019-05-12T14:07:33.257Z</updated>
    
    <content type="html"><![CDATA[<figure class="highlight r"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">it was related to multiple distributed R processes spread over SGE cluster trying to interact with the package index files <span class="keyword">in</span> LIB_PATH and the latency of cleaning up lock file on NFS file system</span><br><span class="line">install.packages(<span class="string">"Rcpp"</span>, dependencies=<span class="literal">TRUE</span>, INSTALL_opts = c(<span class="string">'--no-lock'</span>))</span><br></pre></td></tr></table></figure><p>This happens when your last package installation has interrupted abnormally. to fix this you should remove the locked file</p><figure class="highlight r"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">unlink(<span class="string">"/home/me/src/Rlibs/00LOCK-Rcpp"</span>, recursive = <span class="literal">TRUE</span>)</span><br></pre></td></tr></table></figure><p><a href="https://stackoverflow.com/questions/14382209/r-install-packages-returns-failed-to-create-lock-directory" target="_blank" rel="noopener">https://stackoverflow.com/questions/14382209/r-install-packages-returns-failed-to-create-lock-directory</a></p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;figure class=&quot;highlight r&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td 
      
    
    </summary>
    
      <category term="erro" scheme="http://yoursite.com/categories/erro/"/>
    
    
      <category term="R" scheme="http://yoursite.com/tags/R/"/>
    
  </entry>
  
  <entry>
    <title>李梢--单细胞转录组发现早期胃癌特异标记基因</title>
    <link href="http://yoursite.com/2019/05/12/%E6%9D%8E%E6%A2%A2-%E5%8D%95%E7%BB%86%E8%83%9E%E8%BD%AC%E5%BD%95%E7%BB%84%E5%8F%91%E7%8E%B0%E6%97%A9%E6%9C%9F%E8%83%83%E7%99%8C%E7%89%B9%E5%BC%82%E6%A0%87%E8%AE%B0%E5%9F%BA%E5%9B%A0/"/>
    <id>http://yoursite.com/2019/05/12/李梢-单细胞转录组发现早期胃癌特异标记基因/</id>
    <published>2019-05-12T08:42:05.000Z</published>
    <updated>2019-05-13T14:37:34.813Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://doi.org/10.1016/j.celrep.2019.04.052" target="_blank" rel="noopener">Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer</a></p><h2 id="Abstract"><a href="#Abstract" class="headerlink" title="Abstract"></a>Abstract</h2><ul><li><p>constructed a single-cell atlas for 32,332 high-quality cells from gastric antral mucosa biopsies of patients spanning a cascade of gastric premalignant lesions and early gastric cancer (EGC) using single-cell RNA sequencing</p></li><li><p>We found that gland mucous cells tended to acquire an intestinal-like stem cell phenotype during metaplasia, and we identified <strong>OR51E1</strong> as a marker for unique endocrine cells in the early-malignant lesion.</p></li><li><p>We also found that <strong>HES6</strong> might mark the pre-goblet cell cluster, potentially aiding identification of metaplasia at the early stage.</p></li></ul><h2 id="RESULTS"><a href="#RESULTS" class="headerlink" title="RESULTS"></a>RESULTS</h2><h3 id="A-Single-Cell-Atlas-of-Premalignant-Gastric-Antral-Mucosae-and-EGC"><a href="#A-Single-Cell-Atlas-of-Premalignant-Gastric-Antral-Mucosae-and-EGC" class="headerlink" title="A Single-Cell Atlas of Premalignant Gastric Antral Mucosae and EGC"></a>A Single-Cell Atlas of Premalignant Gastric Antral Mucosae and EGC</h3><p><img src="C:\Users\feng\AppData\Roaming\Typora\typora-user-images\1557755753032.png" alt="1557755753032"></p><ul><li>the atlas mainly comprised epithelial cells (<strong>EPCAM, KRT18, and MUC1</strong>) and non-epithelial cells (<strong>VIM and PTPRC</strong>)</li><li><font color="#F08080"><strong>epithelial cells</strong></font> mainly consisted of gastric epithelial cells, including antral <strong>basal gland mucous cells</strong> (GMCs, marked as MUC6 and TFF2), <strong>pit mucous cells </strong>(PMCs, marked as MUC5AC and TFF1), <strong>chief cells </strong>(PGA4 and PGA3), and <strong>enteroendocrine cells</strong> (CHGA and CHGB)  GMC：基底腺粘液细胞  PMC：坑粘液细胞 chief cell ：主细胞   肠内分泌细胞</li><li>proliferative cells (PCs)  MKI67 and BRIC5</li><li>cancer cells  CEACAM5 and CEACAM6</li><li>metaplastic stem-like cell (MSC)：elevated expression of the intestinal stem cell markers, including OLFM4, EPHB2, and SOX9</li><li><font color="#F08080"><strong>non-epithelial cell lineages</strong></font> comprised T cells (CD2 and CD3D), B cells (CD79A), macrophages (CSF1R and CD68), fibroblasts (DCN and PDPN), smooth muscle cells (SMCs, marked as ACTA2), endothelial cells (ECs, marked as VWF and ENG), and mast cells (TPSAB1)</li><li>FigD:  plot the cell of origin for some mediators in the cytokines and the nuclear factor kB (NF-kB) signaling pathway</li></ul><p>we found that macrophages might be a dominant source of <strong>interleukin-1B (IL-1B)</strong>, whose genotype was reported to confer a greater risk of GC, and <strong>PTGS2</strong>, which plays a crucial role in mediating the inflammatory process through the activation of NF-kB</p><h4 id="H-pylori-幽门螺旋杆菌-的影响"><a href="#H-pylori-幽门螺旋杆菌-的影响" class="headerlink" title="H. pylori(幽门螺旋杆菌)的影响"></a>H. pylori(幽门螺旋杆菌)的影响</h4><p><img src="https://i.loli.net/2019/05/13/5cd97a2caf31b74339.jpg" alt></p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;p&gt;&lt;a href=&quot;https://doi.org/10.1016/j.celrep.2019.04.052&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Dissecting the Single-Cell Transcriptome Network Un
      
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="cancer" scheme="http://yoursite.com/tags/cancer/"/>
    
  </entry>
  
  <entry>
    <title>python dataframe 获取行名和列名</title>
    <link href="http://yoursite.com/2019/05/09/python-dataframe-%E8%8E%B7%E5%8F%96%E8%A1%8C%E5%90%8D%E5%92%8C%E5%88%97%E5%90%8D/"/>
    <id>http://yoursite.com/2019/05/09/python-dataframe-获取行名和列名/</id>
    <published>2019-05-09T14:32:53.000Z</published>
    <updated>2019-05-09T14:36:10.514Z</updated>
    
    <content type="html"><![CDATA[<figure class="highlight python"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">dfname._stat_axis.values.tolist() <span class="comment"># 行名称</span></span><br><span class="line"></span><br><span class="line">dfname.columns.values.tolist()    <span class="comment"># 列名称</span></span><br></pre></td></tr></table></figure>]]></content>
    
    <summary type="html">
    
      
      
        &lt;figure class=&quot;highlight python&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;span clas
      
    
    </summary>
    
    
      <category term="python" scheme="http://yoursite.com/tags/python/"/>
    
  </entry>
  
  <entry>
    <title>pandas.DataFrame更改列名</title>
    <link href="http://yoursite.com/2019/05/09/pandas-DataFrame%E6%9B%B4%E6%94%B9%E5%88%97%E5%90%8D/"/>
    <id>http://yoursite.com/2019/05/09/pandas-DataFrame更改列名/</id>
    <published>2019-05-09T14:28:59.000Z</published>
    <updated>2019-05-09T14:35:39.390Z</updated>
    
    <content type="html"><![CDATA[<figure class="highlight python"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br></pre></td><td class="code"><pre><span class="line"></span><br><span class="line">df.columns.values <span class="comment">## 显示每列的名称</span></span><br><span class="line">df.rename(columns=&#123; df.columns[<span class="number">2</span>]: <span class="string">"new name"</span> &#125;, inplace=<span class="literal">True</span>) <span class="comment">## 将第三列的列名改为'new name'</span></span><br><span class="line">df.columns = [<span class="string">'col_1'</span>, <span class="string">'col_2'</span>, <span class="string">'col_3'</span>]  <span class="comment">## 假如df一共有三列，你想把所有列名依次改为'col_1', 'col_2', 'col_3'</span></span><br><span class="line">df = df.rename(columns=&#123;<span class="string">'col_1'</span>: <span class="string">'col_a'</span>&#125;)</span><br></pre></td></tr></table></figure>]]></content>
    
    <summary type="html">
    
      
      
        &lt;figure class=&quot;highlight python&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;span clas
      
    
    </summary>
    
    
      <category term="python" scheme="http://yoursite.com/tags/python/"/>
    
  </entry>
  
  <entry>
    <title>生物信息--山东大学</title>
    <link href="http://yoursite.com/2019/05/08/%E7%94%9F%E7%89%A9%E4%BF%A1%E6%81%AF-%E5%B1%B1%E4%B8%9C%E5%A4%A7%E5%AD%A6/"/>
    <id>http://yoursite.com/2019/05/08/生物信息-山东大学/</id>
    <published>2019-05-08T12:25:04.000Z</published>
    <updated>2019-05-20T02:09:05.393Z</updated>
    
    <content type="html"><![CDATA[<h2 id="生物数据库"><a href="#生物数据库" class="headerlink" title="生物数据库"></a>生物数据库</h2><h2 id="分类"><a href="#分类" class="headerlink" title="分类"></a>分类</h2><h3 id="核酸数据库"><a href="#核酸数据库" class="headerlink" title="核酸数据库"></a>核酸数据库</h3><p>一级：GeneBank ENA DDBJ</p><p>蛋白数据库：一级   二级</p><p>专用数据库</p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;h2 id=&quot;生物数据库&quot;&gt;&lt;a href=&quot;#生物数据库&quot; class=&quot;headerlink&quot; title=&quot;生物数据库&quot;&gt;&lt;/a&gt;生物数据库&lt;/h2&gt;&lt;h2 id=&quot;分类&quot;&gt;&lt;a href=&quot;#分类&quot; class=&quot;headerlink&quot; title=&quot;分类&quot;&gt;&lt;/a&gt;分
      
    
    </summary>
    
    
      <category term="bioinformatic" scheme="http://yoursite.com/tags/bioinformatic/"/>
    
  </entry>
  
  <entry>
    <title>Gal1 inhibit PDAC via tumor-stroma crosstalk(PNAS_2017)</title>
    <link href="http://yoursite.com/2019/04/30/Gal1-inhibit-PDAC-via-tumor-stroma-crosstalk-PNAS-2017/"/>
    <id>http://yoursite.com/2019/04/30/Gal1-inhibit-PDAC-via-tumor-stroma-crosstalk-PNAS-2017/</id>
    <published>2019-04-30T02:00:48.000Z</published>
    <updated>2019-04-30T14:20:49.472Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910865/" target="_blank" rel="noopener">Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk</a></p><a id="more"></a>]]></content>
    
    <summary type="html">
    
      &lt;p&gt;&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910865/&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk&lt;/a&gt;&lt;/p&gt;
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="cancer" scheme="http://yoursite.com/tags/cancer/"/>
    
  </entry>
  
  <entry>
    <title>Treg中HPGD发挥免疫抑制功能（通过pparg通路）</title>
    <link href="http://yoursite.com/2019/04/25/Treg%E4%B8%ADHPGD%E5%8F%91%E6%8C%A5%E5%85%8D%E7%96%AB%E6%8A%91%E5%88%B6%E5%8A%9F%E8%83%BD%EF%BC%88%E9%80%9A%E8%BF%87pparg%E9%80%9A%E8%B7%AF%EF%BC%89/"/>
    <id>http://yoursite.com/2019/04/25/Treg中HPGD发挥免疫抑制功能（通过pparg通路）/</id>
    <published>2019-04-25T06:21:16.000Z</published>
    <updated>2019-05-20T02:08:15.875Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://doi.org/10.1016/j.immuni.2019.03.014" target="_blank" rel="noopener">Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction</a></p><a id="more"></a><h2 id="Highlights"><a href="#Highlights" class="headerlink" title="Highlights"></a>Highlights</h2><ul><li>HPGD is specifically upregulated in Treg cells and confers suppressive capabilities</li><li>HPGD-induced Tconv cell suppression is in part mediated by PPARγ signaling</li><li>HPGD expression in Treg cells is vital for VAT homeostasis and metabolic regulation</li><li>T2D patients have a reduced Treg cell fraction expressing lower amounts of HPGD</li></ul><h2 id="Summary"><a href="#Summary" class="headerlink" title="Summary"></a>Summary</h2><p>Regulatory T cells (Treg cells) are important for preventing autoimmunity and maintaining tissue homeostasis, but whether Treg cells can adopt tissue- or immune-context-specific suppressive mechanisms is unclear. Here, we found that the enzyme hydroxyprostaglandin dehydrogenase (HPGD), which catabolizes prostaglandin E 2 (PGE 2) into the metabolite 15-keto PGE 2, was highly expressed in Treg cells, particularly those in visceral adipose tissue (VAT). <strong>Nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ)-induced HPGD expression in VAT Treg cells, and consequential Treg-cell-mediated generation of 15-keto PGE 2 suppressed conventional T cell activation and proliferation</strong>. Conditional deletion of Hpgd in mouse Treg cells resulted in the accumulation of functionally impaired Treg cells specifically in VAT, causing local inflammation and systemic insulin resistance. Consistent with this mechanism, humans with type 2 diabetes showed decreased HPGD expression in Treg cells. These data indicate that HPGD-mediated suppression is a tissue- and context-dependent suppressive mechanism used by Treg cells to maintain adipose tissue homeostasis.</p>]]></content>
    
    <summary type="html">
    
      &lt;p&gt;&lt;a href=&quot;https://doi.org/10.1016/j.immuni.2019.03.014&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction&lt;/a&gt;&lt;/p&gt;
    
    </summary>
    
      <category term="paper" scheme="http://yoursite.com/categories/paper/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>免疫学原理</title>
    <link href="http://yoursite.com/2019/04/20/%E5%85%8D%E7%96%AB%E5%AD%A6%E5%8E%9F%E7%90%86/"/>
    <id>http://yoursite.com/2019/04/20/免疫学原理/</id>
    <published>2019-04-20T12:14:05.000Z</published>
    <updated>2019-04-27T05:56:07.251Z</updated>
    
    <content type="html"><![CDATA[<p>非淋巴细胞和固有淋巴细胞  <a href="https://mubu.com/doc/dwcLe46HQw" target="_blank" rel="noopener">https://mubu.com/doc/dwcLe46HQw</a></p><p>免疫原与免疫球蛋白 <a href="https://mubu.com/doc/mpILeMq500" target="_blank" rel="noopener">https://mubu.com/doc/mpILeMq500</a></p><p>主要组织相容性抗原 <a href="https://mubu.com/doc/kcgK6-1kE0" target="_blank" rel="noopener">https://mubu.com/doc/kcgK6-1kE0</a></p><p>固有免疫 <a href="https://mubu.com/doc/gklhh9gUi0" target="_blank" rel="noopener">https://mubu.com/doc/gklhh9gUi0</a></p>]]></content>
    
    <summary type="html">
    
      
      
        &lt;p&gt;非淋巴细胞和固有淋巴细胞  &lt;a href=&quot;https://mubu.com/doc/dwcLe46HQw&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;https://mubu.com/doc/dwcLe46HQw&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;免疫原与免疫球
      
    
    </summary>
    
      <category term="basic" scheme="http://yoursite.com/categories/basic/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>Negative Co-stimulation 控制T细胞分化</title>
    <link href="http://yoursite.com/2019/04/18/Negative%20Co-stimulation%20%E6%8E%A7%E5%88%B6T%E7%BB%86%E8%83%9E%E5%88%86%E5%8C%96/"/>
    <id>http://yoursite.com/2019/04/18/Negative Co-stimulation 控制T细胞分化/</id>
    <published>2019-04-18T05:33:41.000Z</published>
    <updated>2019-05-20T05:44:05.502Z</updated>
    
    <content type="html"><![CDATA[<p><a href="https://doi.org/10.1016/j.immuni.2019.03.004" target="_blank" rel="noopener">Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States</a></p><p>Immunity, 201904</p><a id="more"></a><p>T cell differentiation generates a wide range of specialized cell types; however, how the range of attainable cell states (i.e., phenotypes) is determined remains an open question. Given that T cell differentiation is tightly linked to TCR signal strength, the authors hypothesized that attenuation of downstream TCR signaling by CTLA-4 might also regulate differentiation. In order to verify this, the authors profiled lymphocytes derived from <em>Ctla4-/-</em> and littermate control mice via mass cytometry and subsequently used clustering methods to classify T cell populations. t-SNE visualization illustrated changes in T cell population frequencies and phenotypes in <em>Ctla4-/-</em> mice, but no differences between <em>Ctla4+/+</em> and <em>Ctla4+/-</em> mice were apparent. Populations that were only observed in <em>Ctla4-/-</em> mice were entirely contained within the CD4+ compartment. These enriched CD4+ T cell populations expressed high amounts of CD44 and inducible co-stimulatory molecule (ICOS) but displayed variable levels of other activation markers and lineage transcription factors. For example, the frequency of terminally differentiated (TBET+EOMES+CD44+CD62L+) CD8+ T cells increased in <em>Ctla4-/-</em> mice. Similarly, an ICOS+ Treg cell population that is very minor in CTLA-4 competent mice expanded in frequency in <em>Ctla4-/-</em> mice, whereas other Treg cell populations remained stable or contracted. These findings contrasted with the effects on CD8+ T cells, in which loss of CTLA-4 modulated expression levels (e.g., EOMES, IRF4, and CXCR3), but no CD8+ T cell clusters, was detected only in <em>Ctla4-/-</em> mice. This suggests that CTLA-4 limits CD4+ T cell phenotypes but not those of CD8+ T cells. Next, the authors concurrently assessed changes in 5-iodo-deoxyuridine (IdU) incorporation and changes in frequency in T cell subsets due to loss of CTLA-4 which suggested that there was no correlation between the change in frequency of each T cell subset and the respective changes in IdU incorporation. The phenomenon revealed above raised a question that whether loss of CTLA-4-mediated negative feedback allows cells to occupy otherwise unattainable phenotypic states. Archetypal analysis, an unsupervised computational approach used to identify optimal phenotypes associated with specific biological phenomena at the organismal and single-cell level, helped researchers identified phenotypic boundary and reveals that loss of CTLA-4 expands CD4+ but not CD8+ T cell phenotypic space. Next, because ICOS was highly expressed by phenotypically expanded T cells and antibody blockade of ICOS attenuates T cell activity in <em>Ctla4-/-</em> mice, researchers tested whether ICOS is necessary for the generation of aberrant populations. As a result, all T cell populations identified in <em>Ctla4-/-Icos+/-</em> mice were present in <em>Ctla4-/-Icos-/-</em> mice, indicating that although ICOS is highly expressed on phenotypically expanded subsets, it is not required for their development.</p><p>immunized <em>Ctla4-/-</em> and littermate controls with ovalbumin in complete Freund’s adjuvant (CFA) indicated that extension of phenotypic limits derives directly from loss of CTLA-4 rather than indirect effects of its deletion. Then, analysis of TCRβ repertoire of thymic and LN tissue from <em>Ctla4-/-</em> and littermate control mice revealed that no major molecular defects in thymic T cell repertoire or the frequency of productive rearrangements were detected. In contrast, T cell clonality increased in <em>Ctla4-/-</em> LN tissue. Increased clonality was accompanied by decreased average CDR3 length, in part resulting from a decrease in N1 and N2 nucleotides inserted at V-D and D-J junctions. On the other hand, analysis of PD1 suggested that PD1 mainly affected CD8+ populations but the subtle expansion of CD8+ T cell phenotype limits due to loss of PD-1 appears to be age dependent and most likely relies on the prior induction of an immune response. Finally, the authors used mass cytometry data to reconstruct differentiation trajectories between the naive CD4+ T cell archetype and each differentiated CD4+ T cell archetype. Along the trajectory, the authors investigated that a subset of markers (such as PD1) expression continued to increase beyond the boundary which suggested that a primary mechanism by which CTLA-4 restrains T cell phenotypes is through imposing maximal limits on already active pathways.</p><p>In summary, this paper revealed that (1) T cell negative co-stimulation regulates the limits of T cell differentiation, a role related to but distinct from its regulation of T cell activation; (2) CTLA-4 enforces boundaries on CD4+ T cell phenotypes; (3) PD-1 subtly restrains CD8+ T cell phenotypes; and (4) CTLA-4 constrains T cell phenotypes by imposing maximal expression limits during differentiation. These finding support the “nuanced model” in which T cell subsets represent a continuum of interrelated phenotypic states, defined by ratios of co-expression of lineage transcription factors, rather than discrete lineages. It remains to be assessed whether the expanded phenotypes represent stable terminally differentiated states or rather transient intermediate states not normally attainable.</p><p><img src="https://i.loli.net/2019/04/27/5cc3ee0aa5855.jpg" alt></p>]]></content>
    
    <summary type="html">
    
      &lt;p&gt;&lt;a href=&quot;https://doi.org/10.1016/j.immuni.2019.03.004&quot; target=&quot;_blank&quot; rel=&quot;noopener&quot;&gt;Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Immunity, 201904&lt;/p&gt;
    
    </summary>
    
      <category term="daily" scheme="http://yoursite.com/categories/daily/"/>
    
    
      <category term="immunity" scheme="http://yoursite.com/tags/immunity/"/>
    
  </entry>
  
  <entry>
    <title>tool</title>
    <link href="http://yoursite.com/2019/04/13/tool/"/>
    <id>http://yoursite.com/2019/04/13/tool/</id>
    <published>2019-04-13T14:29:48.000Z</published>
    <updated>2019-04-27T05:55:50.124Z</updated>
    
    <content type="html"><![CDATA[<h2 id="CytoSPADE"><a href="#CytoSPADE" class="headerlink" title="CytoSPADE"></a>CytoSPADE</h2><blockquote><p>A high-performance implementation of an interface for the Spanning-tree Progression Analysis of Density-normalized Events algorithm for tree-based analysis and visualization of this high-dimensional cytometry data</p></blockquote><a id="more"></a><h2 id="PhenoGraph"><a href="#PhenoGraph" class="headerlink" title="PhenoGraph"></a>PhenoGraph</h2><blockquote><p><a href="http://www.cell.com/cell/abstract/S0092-8674(15" target="_blank" rel="noopener">PhenoGraph</a>00637-6) is a clustering method designed for high-dimensional single-cell data. It works by creating a graph (“network”) representing phenotypic similarities between cells and then identifying communities in this graph.</p></blockquote><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28865188" target="_blank" rel="noopener">PhenoGraph and viSNE facilitate the identification of abnormal T-cell populations in routine clinical flow cytometric data.</a></p><p><a href="https://www.cell.com/cell/fulltext/S0092-8674(15" target="_blank" rel="noopener">Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis</a>00637-6&gt;)</p><h2 id="Louvain"><a href="#Louvain" class="headerlink" title="Louvain"></a>Louvain</h2><p><img src="https://i.loli.net/2019/04/18/5cb81b8c5430c.jpg" alt></p><p><a href="https://sites.google.com/site/findcommunities/" target="_blank" rel="noopener">Louvain method: Finding communities in large networks</a></p>]]></content>
    
    <summary type="html">
    
      &lt;h2 id=&quot;CytoSPADE&quot;&gt;&lt;a href=&quot;#CytoSPADE&quot; class=&quot;headerlink&quot; title=&quot;CytoSPADE&quot;&gt;&lt;/a&gt;CytoSPADE&lt;/h2&gt;&lt;blockquote&gt;
&lt;p&gt;A high-performance implementation of an interface for the Spanning-tree Progression Analysis of Density-normalized Events algorithm for tree-based analysis and visualization of this high-dimensional cytometry data&lt;/p&gt;
&lt;/blockquote&gt;
    
    </summary>
    
    
      <category term="杂记" scheme="http://yoursite.com/tags/%E6%9D%82%E8%AE%B0/"/>
    
  </entry>
  
</feed>
